Abstract Titles

Skip to Late-Breaking Abstracts »

All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Onsite Posters

Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.


ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.

Search word or phrase:

# Type Title Authors Category Keywords
628 Poster Presentation Real-world clinical outcomes among patients with advanced Merkel cell carcinoma treated with avelumab in academic medical centers in the United States Shailender Bhatia, MD; Paul T. Nghiem, MD, PhD; S Phani Veeranki; Alejandro Vanegas; Kristina Lachance; Lisa Tachiki; Kevin Chiu; Emily Boller; Murtuza Bharmal, PhD, MS, BPharm Education and Treatment Management Checkpoint blockade;Clinical study;Epidemiology;Solid tumors
629 Poster Presentation Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors Priyanka V. Chablani, MD; Theodore Karrison, PhD; Walter Stadler, MD Education and Treatment Management Checkpoint blockade;Chemotherapy;Clinical study;Solid tumors
630 Poster Presentation Oncologists’ perspectives on evolution of first-line immune checkpoint inhibitor maintenance therapy in management of advanced urothelial carcinoma in the US Petros Grivas; Phani Veeranki; Kevin Chiu; Vivek Pawar; Jane Chang; Murtuza Bharmal, PhD, MS, BPharm Education and Treatment Management Checkpoint blockade;Chemotherapy;Clinical study;Solid tumors
631 Poster Presentation Deep, durable response to PD-1 inhibitor monotherapy in microsatellite-stable, tumor mutational burden-high colorectal cancer Samuel J. Schellenberg, BS; Leeseul Kim, MD; Young Kwang Chae, MD, MPH, MBA Education and Treatment Management Biomarkers;Checkpoint blockade;Neoantigens;Solid tumors;Tumor antigens
632 Poster Presentation Toripalimab combined with platinum-based chemotherapy as a second-line treatment for small cell lung cancer (SCLC) with brain metastases: A case report Jieqiong Fan; Yao Zhang; Xiaofei Mo; Jing Guo Education and Treatment Management Antibody;Checkpoint blockade;Solid tumors
633 Poster Presentation Incorporating Checkpoint Inhibitors into Cancer Care: A study of the impact of digital education on clinical competence and practice patterns Tariqa Ackbarali, MS, PhD(c); Elizabeth L. del Nido, BA; Brian I. Rini, MD; Michael J. Overman, MD; Ignacio I. Witsuba, MD Education and Treatment Management Biomarkers;Checkpoint blockade;Immune toxicity;Solid tumors;Tumor microenvironment
635 Poster Presentation Online CME improves the interprofessional team’s ability to manage patients with malignant pleural mesothelioma Michelle A. Worst, PharmD, BCOP, MBA; Emily Van Laar; Megan Whitney, DMD; Anne Tsao, MD; Hossein Borghaei, MS, DO Education and Treatment Management Checkpoint blockade;Chemotherapy;Epidemiology;Immune toxicity;Solid tumors;Targeted therapy;Tumor microenvironment
636 Poster Presentation Patient-Reported Distress with Immunotherapy-Based First-Line Treatment for mNSCLC: a Real-World Evidence Study Monica H. Bodd, BA; Susan C. Locke, PhD; Scott Antonia, MD, PhD; Jeffrey Crawford, MD; John Hartman, PhD; Kris Herring, PhD; Neal Ready, MD, PhD; Thomas E. Stinchcombe, MD; Jesse D. Troy, PhD; Chakita Williams, PhD; Steven Wolf, MS; Jeffrey M. Clarke, MD; Thomas W. LeBlanc, MD MA MHS FAAHPM FASCO Education and Treatment Management Chemotherapy;Clinical study;Solid tumors
637 Poster Presentation Exploring the Impact of Immunotherapy on Cancer Patients’ Real World Experience Helen M. Nichols, PhD; Helen M. Nichols, PhD, MSW; Elise Wu Education and Treatment Management Targeted therapy